The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback